Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4

Current Opinion in Investigational Drugs

Volumn 10, Issue 6, 2009, Pages 526-535

  Kalinski, Pawel ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemokine; CTL; Cytokine; Dendritic cell; IL 12; Immunotherapy; NK cell; Th1; Vaccine

Indexed keywords

CANCER VACCINE; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; INTERLEUKIN 12;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE HOMING; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINATION; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOKINES; DENDRITIC CELLS; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 67650650986     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin (2008) 58(2):71-96.
2. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA et al: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 100(23):1672- 1694.
3. Nauts HC: Bacteria and cancer: Antagonisms and benefts. Cancer Surv (1989) 8(4):713-723.
4. Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T: Contrasting frequencies of antitumor and anti-vaccine T-cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 201(2):249-257.
5. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A: Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol (2003) 171(9):4893-4897.
6. Schlom J, Arlen PM, Gulley JL: Cancer vaccines: Moving beyond current paradigms. Clin Cancer Res (2007) 13(13):3776-3782.
7. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5(4):296-306.
8. Blattman JN, Greenberg PD: Cancer immunotherapy: A treatment for the masses. Science (2004) 305(5681):200-205.
9. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: Mapping the way. Nat Med (2004) 10(5):475-480.
10. Gilboa E: The promise of cancer vaccines. Nat Rev Cancer (2004) 4(5):401-411.
11. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
12. Srivastava PK: Therapeutic cancer vaccines. Curr Opin Immunol (2006) 18(2):201-205.
13. Schlom J, Gulley JL, Arlen PM: Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) (2008) 233(5):522-534.
14. Patel PH, Kockler DR: Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother (2008) 42(1):91-98.
15. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianó A, Santantonio C, Tosi D et al: A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol Immunother (2006) 55 (8):958-968.
16. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunsaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC-8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19):3089-3094.
17. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE et al: Combined clinical trial results of a HER2/neu (E-75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res (2008) 14(3):797-803.
18. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumor immunity: Effector response to tumor and role of the microenvironment. Lancet (2008) 371(9614):771-783.
19. Haring JS, Badovinac VP, Harty JT: Infaming the CD8+ T-cell response. Immunity (2006) 25(1):19-29.
20. Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, Hoffmann F, Hector A, Eber E, Marcos V, Bittmann I, Eickelberg O et al: Infltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic infammatory lung diseases. J Immunol (2008) 181(11):8053-8067.
21. Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 25:267-296.
22. Gabrilovich D: Mechanisms and functional signifcance of tumor-induced dendritic-cell defects. Nat Rev Immunol (2004) 4(12):941-952.
23. Gabrilovich D, Pisarev V: Tumor escape from immune response: Mechanisms and targets of activity. Curr Drug Targets (2003) 4(7):525-536.
24. Zou W: Regulatory T-cells, tumor immunity and immunotherapy. Nat Rev Immunol (2006) 6(4):295-307.
25. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y et al: Specifc recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10(9):942-949.
26. Vieweg J, Su Z, Dahm P, Kusmartsev S: Reversal of tumor-mediated immunosuppression. Clin Cancer Res (2007) 13 (2 Pt 2):727s-732s.
27. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM: Expansion of FOXP3high regulatory T-cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 108(8):2655-2661.
28. Yang L, Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res (2004) 92:13-27.
29. Pinzon-Charry A, Maxwell T, López JA: Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol Cell Biol (2005) 83(5):451-461.
30. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, Yang D, Danenberg KD, Danenberg PV: Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fuoropyrimidine-based chemotherapy. Clin Cancer Res (2005) 11(9):3363-3368.
31. Williams C, Shattuck-Brandt RL, DuBois RN: The role of COX-2 in intestinal cancer. Ann NY Acad Sci (1999) 889:72-83.
32. Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, Yamashina I, Inoue M, Nakada H: Induction of cyclooxygenase-2 in monocyte/ macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci USA (2003) 100(5):2736-2741.
33. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: A signifcant prognostic indicator for patients with colorectal cancer. Clin Cancer Res (2004) 10(24):8465- 8471.
34. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P: Ability of mature dendritic cells to interact with regulatory T-cells is imprinted during maturation. Cancer Res (2008) 68(14):5972- 5978.
35. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol (2001) 166(1):678-689.
36. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical signifcance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 6(5):1755-1766.
37. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 166(9):5398-5406.
38. Young MR, Wright MA, Lozano Y, Prechel MM, Benefeld J, Leonetti JP, Collins SL, Petruzzelli GJ: Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer (1997) 74(1):69-74.
39. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 190(10):1417- 1426.
40. Toriyama K, Wen DR, Paul E, Cochran AJ: Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol (1993) 100(3):269S-273S.
41. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res (1998) 4(3):585-593.
42. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, saeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T et al : Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 7(12):1339-1346.
43. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML: Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 89(8):1463-1472
44. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T-cells. J Clin Invest (2005) 115(12):3623-3633.
45. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature (2007) 449(7161):419-426.
46. Steinman RM, Adams JC, Cohn ZA: Identifcation of a novel cell type in peripheral lymphoid organs of mice. IV. Identifcation and distribution in mouse spleen. J Exp Med (1975) 141 (4):804-820.
47. Steinman RM, Cohn ZA: Identifcation of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 137(5):1142-1162.
48. Steinman RM, Cohn ZA: Identifcation of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med (1974) 139(2):380-397.
49. Steinman RM, Lustig DS, Cohn ZA: Identifcation of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med (1974) 139(6):1431-1445
50. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM: Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA (2006) 103(30):11252-11257
51. Kaliński P, Hilkens CM, Wierenga EA, Kapsenberg ML: T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today (1999) 20(12):561-567.
52. Kaliński P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML: Final maturation of dendritic cells is associated with impaired responsiveness to IFN and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol (1999) 162(6):3231-3236.
53. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol (2000) 164(9):4507-4512.
54. Kaliński P, Schuitemaker JH, Hilkens CM, Kapsenberg ML: Prostaglandin E2 induces the fnal maturation of IL-12-defcient CD1a+CD83+ dendritic cells: The levels of IL-12 are determined during the fnal dendritic cell maturation and are resistant to further modulation. J Immunol (1998) 161 (6):2804-2809.
55. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252
56. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 15(2):138-147.
57. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med (1997) 186(8):1183-1187.
58. Kapsenberg ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol (2003) 3(12):984-993
59. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T: The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci (2004) 95(9):697-703.
60. Pulendran B: Modulating Th1/Th2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res (2004) 29(1-3):187-196.
61. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 3(2):133-146.
62. Palucka K, Banchereau J: How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol (2002) 14(4):420-431.
63. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I: Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol (2001) 21(1-3):157-178.
64. Kalinski P, Moser M: Consensual immunity: Success-driven development of T-helper-1 and T-helper-2 responses. Nat Rev Immunol (2005) 5(3):251-260.
65. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate antitumor immune responses in vivo. Nat Med (1999) 5(4):405-411.
66. Gustafsson K, Ingelsten M, Bergqvist L, Nyström J, Andersson B, Karlsson-Parra A: Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res (2008) 68(14):5965-5971.
67. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest (1999) 104(2):173-180.
68. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG et al: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 9(14):5091-5100.
69. Adema GJ, de Vries IJ, Punt CJ, Figdor CG: Migration of dendritic cell-based cancer vaccines: In vivo veritas? Curr Opin Immunol (2005) 17(2):170-174.
70. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ et al: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 63(1):12-17.
71. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T-cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 183(1):87-97.
72. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT: Interleukin-12 and B7.1 costimulation co-operate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol (1996) 26(6):1335-1341.
73. Furumoto K, Arii S, Yamasaki S, Mizumoto M, Mori A, Inoue N, Isobe N, Imamura M: Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer (2000) 87(5):665-672.
74. Furumoto K, Mori A, Yamasaki S, Inoue N, Yang W, Nakau M, Yasuda S, Arii S, Imamura M: Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective inducer of tumor-specifc immunity in a peritoneal dissemination model. Immunol Lett (2002) 83(1):13-20.
75. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modifed to express interleukin-12. Cancer Res (1999) 59(16):4035-4041.
76. Okada N, Iiyama S, Okada Y, Mizuguchi H, Hayakawa T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A: Immunological properties and vaccine effcacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther (2005) 12(1):72-83.
77. Redlinger RE Jr, Mailliard RB, Barksdale EM Jr: Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy. J Pediatr Surg (2003) 38(6):857-862.
78. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR: Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol (2002) 2(6):337-349.
79. Shimizu T, Berhanu A, Redlinger RE Jr, Watkins S, Lotze MT, Barksdale EM Jr: Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg (2001) 36(8):1285-1292.
80. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R, Blaese M, Xanthopoulos KG: Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modifed dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg (2002) 97(3):611-618.
81. Zhang S, Zeng G, Wilkes DS, Reed GE, McGarry RC, Eble JN, Cheng L: Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo. Prostate (2003) 55(4):292-298.
82. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2(1):52-58.
83. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4(3):328-332.
84. Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-infammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 27(12):3135-3142.
85. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and non-polarized T-cells. Nat Immunol (2000) 1(4):311-316.
86. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P: α-Type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 64(17):5934-5937.
87. 2 regulates the migratory capacity of specifc DC subsets. Blood (2002) 100(4):1362-1372.
88. Scandella E, Men Y, Gillessen S, Förster R, Groettrup M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 100(4):1354- 1361.
89. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB: Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol (2005) 42(4):535- 539.
90. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 5(10):1303-1315.
91. Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ, Kalinski P: Complementary dendritic cell-activating function of CD8+ and CD4+ T-cells: Helper role of CD8+ T-cells in the development of T-helper type 1 responses. J Exp Med (2002) 195(4):473-483.
92. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P: Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 171(5):2366-2373.
93. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ: Rapid high effciency sensitization of CD8+ T-cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 171(5):2251-2261.
94. Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ: Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient Th1-type antimelanoma CD4+ T-cell responses in vitro. J Immunother (2007) 30(1):75-82.
95. Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB: Helper roles of NK and CD8+ T-cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res (2006) 36(1-3):137-146.
96. Ten Brinke A, Karsten ML, Dieker MC, Zwaginga JJ, van Ham SM: The clinical grade maturation cocktail monophosphoryl lipid A plus IFNγ generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine (2007) 25(41):7145-7152.
97. Tarbell KV, Petit L, Zuo X, Toy P, Luo X, Mqadmi A, Yang H, Suthanthiran M, Mojsov S, Steinman RM: Dendritic cell-expanded, islet-specifc CD4+ CD25+ CD62L+ regulatory T-cells restore normoglycemia in diabetic NOD mice. J Exp Med (2007) 204(1):191-201.
98. Yamazaki S, Inaba K, Tarbell KV, Steinman RM: Dendritic cells expand antigen-specifc Foxp3+ CD25+ CD4+ regulatory T-cells including suppressors of alloreactivity. Immunol Rev (2006) 212:314-329.
99. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM: Direct expansion of functional CD25+ CD4+ regulatory T-cells by antigen-processing dendritic cells. J Exp Med (2003) 198(2):235-247.
100. Dhodapkar MV, Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specifc CD8+ regulatory T-cells in vivo in humans. Blood (2002) 100(1):174-177.
101. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P: Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol (2008) 84(1):319-825.
102. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol (2005) 17(2):163-169.
103. No authors listed: Sipuleucel-T: APC-8015, APC-8015, prostate cancer vaccine - Dendreon. Drugs R D (2006) 7(3):197-201.
104. Harzstark AL, Small EJ: Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC-8015 (Provenge). Expert Opin Biol Ther (2007) 7(8):1275-1280.
105. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C et al: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in frst-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol (2006) 17(4):563-570.
106. 2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood (2001) 97(11):3466-3469.
107. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, Palucka AK: IL-15-induced human DC effciently prime melanoma-specifc naive CD8+ T-cells to differentiate into CTL. Eur J Immunol (2007) 37(6):1678-1690.
108. Nguyen LT, Radhakrishnan S, Ciric B, Tamada K, Shin T, Pardoll DM, Chen L, Rodriguez M, Pease LR: Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 196(10):1393-1398.
109. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q: Tumor evasion of the immune system: Inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood (2006) 107(6):2432-2439.
110. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, Dunne P et al: Attenuating regulatory T-cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their effcacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 180(6):3797-3806.
111. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood (1997) 90(5):1920-1926.
112. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML: High-level IL-12 production by human dendritic cells requires two signals. Int Immunol (1998) 10(11):1593-1598.
113. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C: CD40 triggering of heterodimeric IL-12p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity (2000) 13(4):453-462.
114. Spörri R, Reis e Sousa C: Infammatory mediators are insuffcient for full dendritic cell activation and promote expansion of CD4+ T-cell populations lacking helper function. Nat Immunol (2005) 6(2):163-170.
115. Berg EL, Goldstein LA, Jutila MA, Nakache M, Picker LJ, Streeter PR, Wu NW, Zhou D, Butcher EC: Homing receptors and vascular addressins: Cell adhesion molecules that direct lymphocyte traffc. Immunol Rev (1989) 108:5-18.
116. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC: ELAM-1 is an adhesion molecule for skin-homing T-cells. Nature (1991) 349(6312):796-799.
117. Picker LJ, Terstappen LW, Rott LS, Streeter PR, Stein H, Butcher EC: Differential expression of homing-associated adhesion molecules by T-cell subsets in man. J Immunol (1990) 145(10):3247-3255.
118. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR, Terstappen LW: Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T-cells. J Immunol (1993) 150(3):1122-1136.
119. Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffc through the analysis of chemokine receptor expression. Immunol Rev (2000) 177:134-140.
120. Sallusto F, Mackay CR: Chemoattractants and their receptors in homeostasis and infammation. Curr Opin Immunol (2004) 16(6):724-731.
121. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol (2000) 18:593-620.
122. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Márquez G, Agace W: Selective generation of gut tropic T-cells in gut-associated lymphoid tissue (GALT): Requirement for GALT dendritic cells and adjuvant. J Exp Med (2003) 198(6):963-969.
123. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH: Selective imprinting of gut-homing T-cells by Peyer's patch dendritic cells. Nature (2003) 424(6944):88-93.
124. Mora JR, Cheng G, Picarella D, Briskin M, Buchanan N, von Andrian UH: Reciprocal and dynamic control of CD8 T-cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med (2005) 201(2):303-316.
125. Mora JR, von Andrian UH: Retinoic acid: An educational 'vitamin elixir' for gut-seeking T-cells. Immunity (2004) 21 (4):458-460
126. Stagg AJ, Kamm MA, Knight SC: Intestinal dendritic cells increase T-cell expression of α4p7 integrin. Eur J Immunol (2002) 32(5):1445-1454.
127. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY Retinoic acid imprints gut-homing specifcity on T-cells. Immunity (2004) 21(4):527-538.
128. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC: DCs metabolize sunlight-induced vitamin D3 to program' T-cell attraction to the epidermal chemokine CCL27. Nat Immunol (2007) 8(3):285-293.
129. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Rüegg C, Dietrich PY, Walker PR: Homing phenotypes of tumor-specifc CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity (2005) 22(2):175-184.
130. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A: Peripheral burst of tumor-specifc cytotoxic T-lymphocytes and infltration of metastatic lesions by memory CD8+ T-cells in melanoma patients receiving interleukin 12. Cancer Res (2000) 60(13):3559-3568.
131. Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Pedersen LØ, Schuler-Thurner B, Hohenberger W, Straten Pt P, Schuler G, Becker JC: Circulation and homing of melanoma-reactive T-cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer (2004) 111(2):229-237.
132. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer (2005) 104(6):1246-1254
133. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960-1964.
134. Galon J, Fridman WH, Pagès F: The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res (2007) 67(5):1883-1886.
135. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T et al: Effector memory T-cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 353(25):2654-2666.
136. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 64(21):7697-7701.
137. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Bröcker E, Gillitzer R: Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infltration of T-cells in human malignant melanoma. J Pathol (1999) 189(4):552-558.
138. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O: Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T-cells in lymphocyte-rich gastric carcinoma. J Pathol (2009) 217(1):21-31.
139. Schaerli P, Loetscher P, Moser B: Cutting edge: Induction of follicular homing precedes effector Th cell development. J Immunol (2001) 167(11):6082-6086.
140. Weninger W, Manjunath N, von Andrian UH: Migration and differentiation of CD8+ T-cells. Immunol Rev (2002) 186:221-233.